Drug Profile
Research programme: recombinant human protein therapeutics - Pharming/Shanghai Institute of Pharmaceutical Industry
Alternative Names: Recombinant human Factor VIII; rhFVIIILatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Pharming Group NV; Renova Life; Shanghai Institute of Pharmaceutical Industry
- Developer Pharming Group NV; Shanghai Institute of Pharmaceutical Industry
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Haemophilia-A in China
- 17 Jan 2020 Early research development is still ongoing in Haemophilia-A in China
- 14 Jan 2020 Pharming and China State Institute of Pharmaceutical Industry plan preclinical trial for Haemophilia A